{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T07:58:20Z","timestamp":1785484700221,"version":"3.56.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"vor","delay-in-days":99,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research Reports"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.lrr.2026.100589","type":"journal-article","created":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T09:14:56Z","timestamp":1775898896000},"page":"100589","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["The role of RAS mutations in leukemia progression, differentiation, and drug resistance"],"prefix":"10.1016","volume":"25","author":[{"given":"Congfa","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hangxuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuwei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7682-2877","authenticated-orcid":false,"given":"Shiwei","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"14","key":"10.1016\/j.lrr.2026.100589_bib0001","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1158\/0008-5472.CAN-19-3682","article-title":"The frequency of RAS mutations in cancer","volume":"80","author":"Prior","year":"2020","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.lrr.2026.100589_bib0002","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s12185-012-1033-x","article-title":"RAS mutations are frequent in FAB type M4 and M5 of acute myeloid leukemia, and related to late relapse: a study of the Japanese childhood AML cooperative study group","volume":"95","author":"Sano","year":"2012","journal-title":"Int. J. Hematol."},{"issue":"1","key":"10.1016\/j.lrr.2026.100589_bib0003","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1600-0609.2006.00663.x","article-title":"Frequency of RAS gene mutation and its cooperative genetic events in southeast Asian adult acute myeloid leukemia","volume":"77","author":"Auewarakul","year":"2006","journal-title":"Eur. J. Haematol."},{"issue":"40","key":"10.1016\/j.lrr.2026.100589_bib0004","first-page":"3152","article-title":"Coexisting mutations in NPM1-mutated elderly adults with acute myeloid leukemia]","volume":"99","author":"Qin","year":"2019","journal-title":"Zhonghua Yi Xue Za Zhi"},{"issue":"1","key":"10.1016\/j.lrr.2026.100589_bib0005","first-page":"39","article-title":"Clinical significance of common leukemia gene mutations in patients with acute promyelocytic leukemia]","volume":"21","author":"Yin","year":"2013","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"issue":"3","key":"10.1016\/j.lrr.2026.100589_bib0006","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/sj.leu.2403274","article-title":"Acquisition of FLT3 or N-ras mutations is frequently associated with progression of myelodysplastic syndrome to acute myeloid leukemia","volume":"18","author":"Shih","year":"2004","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.lrr.2026.100589_bib0007","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1182\/blood-2005-03-0867","article-title":"RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years","volume":"106","author":"Bowen","year":"2005","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.lrr.2026.100589_bib0008","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood-2016-01-693879","article-title":"Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia","volume":"128","author":"Metzeler","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.lrr.2026.100589_bib0009","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.gde.2016.03.011","article-title":"Genetic and epigenetic heterogeneity in acute myeloid leukemia","volume":"36","author":"Li","year":"2016","journal-title":"Curr. Opin. Genet. Dev."},{"issue":"6","key":"10.1016\/j.lrr.2026.100589_bib0010","first-page":"1811","article-title":"[Analysis of gene mutation and clinical characteristics in 19 children with juvenile myelomonocytic leukemia]","volume":"28","author":"Weng","year":"2020","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"10.1016\/j.lrr.2026.100589_bib0011","first-page":"115","article-title":"The prognostic impact of K-RAS mutations in adult acute myeloid leukemia patients treated with high-dose cytarabine","volume":"4","author":"Ahmad","year":"2011","journal-title":"Onco. Targets Ther."},{"issue":"5","key":"10.1016\/j.lrr.2026.100589_bib0012","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/ajh.23652","article-title":"BRAF kinase domain mutations are present in a subset of chronic myelomonocytic leukemia with wild-type RAS","volume":"89","author":"Zhang","year":"2014","journal-title":"Am. J. Hematol."},{"issue":"1","key":"10.1016\/j.lrr.2026.100589_bib0013","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/s41418-025-01561-0","article-title":"The m6A methyltransferase METTL14 promotes oncogenic Kras induced juvenile myelomonocytic leukemia through dysregulating autophagy","volume":"33","author":"Zhang","year":"2026","journal-title":"Cell Death Differ."},{"issue":"10","key":"10.1016\/j.lrr.2026.100589_bib0014","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.29771","article-title":"Activation of the mitogen-activated protein kinase-extracellular signal-regulated kinase pathway in childhood B-cell acute lymphoblastic leukemia","volume":"69","author":"Pillai","year":"2022","journal-title":"Pediatr. Blood Cancer."},{"issue":"4","key":"10.1016\/j.lrr.2026.100589_bib0015","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/sj.leu.2401369","article-title":"Lack of constitutive activation of MAP kinase pathway in human acute myeloid leukemia cells with N-Ras mutation","volume":"13","author":"Iida","year":"1999","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.lrr.2026.100589_bib0016","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1182\/blood.2025030558","article-title":"Multiselective RAS(ON) inhibition targets oncogenic RAS and overcomes RAS-mediated resistance to FLT3i and BCL2i in AML","volume":"147","author":"Popescu","year":"2026","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.lrr.2026.100589_bib0017","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.lrr.2026.100589_bib0018","doi-asserted-by":"crossref","first-page":"14835","DOI":"10.18632\/oncotarget.11730","article-title":"MEK inhibition is a promising therapeutic strategy for MLL-rearranged infant acute lymphoblastic leukemia patients carrying RAS mutations","volume":"8","author":"Kerstjens","year":"2017","journal-title":"Oncotarget"},{"issue":"9","key":"10.1016\/j.lrr.2026.100589_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.113084","article-title":"CBFA2T3-GLIS2-dependent pediatric acute megakaryoblastic leukemia is driven by GLIS2 and sensitive to navitoclax","volume":"42","author":"Neault","year":"2023","journal-title":"Cell Rep."},{"issue":"5","key":"10.1016\/j.lrr.2026.100589_bib0020","doi-asserted-by":"crossref","first-page":"745","DOI":"10.3892\/ol.2021.13006","article-title":"Pan-RAF inhibitor LY3009120 is highly synergistic with low-dose cytarabine, but not azacitidine, in acute myeloid leukemia with RAS mutations","volume":"22","author":"Park","year":"2021","journal-title":"Oncol. Lett."},{"issue":"1","key":"10.1016\/j.lrr.2026.100589_bib0021","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s11899-006-0013-8","article-title":"Farnesyltransferase inhibitors in myelodysplastic syndrome","volume":"1","author":"Feldman","year":"2006","journal-title":"Curr. Hematol. Malig. Rep."},{"issue":"3","key":"10.1016\/j.lrr.2026.100589_bib0022","first-page":"186","article-title":"Farnesyltransferase inhibitors in myelodysplastic syndrome","volume":"4","author":"Feldman","year":"2005","journal-title":"Curr. Hematol. Rep."},{"issue":"5","key":"10.1016\/j.lrr.2026.100589_bib0023","first-page":"548","article-title":"Genetic and clinical characteristics of children with RAS-mutated juvenile myelomonocytic leukemia]","volume":"27","author":"Chen","year":"2025","journal-title":"Zhongguo Dang Dai Er Ke Za Zhi"},{"issue":"4","key":"10.1016\/j.lrr.2026.100589_bib0024","first-page":"343","article-title":"The prognostic impact of K-RAS mutations in adult acute myeloid leukemia patients treated with high dose cytarabine","volume":"21","author":"Ahmad","year":"2009","journal-title":"J. Egypt Natl. Canc. Inst."},{"issue":"2","key":"10.1016\/j.lrr.2026.100589_bib0025","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8020200","article-title":"Chimeric Antigen Receptor (CAR) T Cell Therapy in Acute Myeloid Leukemia (AML)","volume":"8","author":"Hofmann","year":"2019","journal-title":"J. Clin. Med."},{"issue":"4","key":"10.1016\/j.lrr.2026.100589_bib0026","first-page":"365","article-title":"Clinical and genetic analyses of juvenile myelomonocytic leukemia","volume":"21","author":"Zeng","year":"2019","journal-title":"Zhongguo Dang Dai Er Ke Za Zhi"},{"issue":"1","key":"10.1016\/j.lrr.2026.100589_bib0027","first-page":"1","article-title":"Gene mutations and clinical characteristics in children with juvenile myelomonocytic leukemia","volume":"17","author":"Yang","year":"2015","journal-title":"Zhongguo Dang Dai Er Ke Za Zhi"},{"issue":"13","key":"10.1016\/j.lrr.2026.100589_bib0028","doi-asserted-by":"crossref","first-page":"4632","DOI":"10.1002\/cam4.3099","article-title":"High incidence of RAS pathway mutations among sentinel genetic lesions of Korean pediatric BCR-ABL1-like acute lymphoblastic leukemia","volume":"9","author":"Lee","year":"2020","journal-title":"Cancer Med."}],"container-title":["Leukemia Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213048926000294?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213048926000294?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T07:11:08Z","timestamp":1785481868000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213048926000294"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":28,"alternative-id":["S2213048926000294"],"URL":"https:\/\/doi.org\/10.1016\/j.lrr.2026.100589","relation":{},"ISSN":["2213-0489"],"issn-type":[{"value":"2213-0489","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of RAS mutations in leukemia progression, differentiation, and drug resistance","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lrr.2026.100589","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100589"}}